Food and Drug Administration (FDA)
NEWS
Three other drug contenders that work similarly to Biogen’s drug are currently in clinical trials and expecting data relatively soon.
Findings from the study suggest the oral JAK inhibitor tofacitinib could be a potential contender in the race to identify benefits for COVID-19 in already approved therapies.
The FDA granted it to Lu-PSMA-617, an investigational radioligand therapy to treat metastatic castration-resistant prostate cancer.
Biogen’s quest to develop additional medicines for Alzheimer’s disease beyond its newly-approved aducanumab has hit a clinical snag after gosuranemab failed.
Biotech companies are dominating Nasdaq’s IPO scheduled this week. Here’s who is making their big public debut.
The U.S. FDA approved Ayvakit for the treatment of adult patients with advanced sytematic mastocytosis (SM), advanced SM, and mast cell leukemia.
Both MannKind and United Therapeutics entered into a global and exclusive licensing and collaboration agreement to develop and commercialize Tyvaso DPI.
In an eight page letter to U.S. DOH and Human Services Secretary Xavier Becerra, Public Citizen said Woodcock and other FDA officials should resign.
The new data shows REGEN-COV reduced the risk of death in hospitalized patients unable to mount their own immune response by 20%.
JOBS
IN THE PRESS